Perrigo CoLTS:0Y5E -5.10%49 3-Year Revenue Growth Rate is -2.50% as of Mar. 2026. GuruFocus rates LTS:0Y5E with a GF Score™ of 49/100 and a GF Value™ of $25.05 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 899 Drug Manufacturers companies, Perrigo Co ranks worse than 68.52% on this metric.
During the past 12 months, Perrigo Co's average Revenue per Share Growth Rate was -4.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -2.50% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 0.80% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -0.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Perrigo Co was 17.50% per year. The lowest was -8.40% per year. And the median was 5.30% per year.
Perrigo Co (LTS:0Y5E) 3-Year Revenue Growth Rate Explanation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.
Perrigo Co 3-Year Revenue Growth Rate Related Terms
LTS:0Y5E vs AMLX, HROW, ANIP: 3-Year Revenue Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Perrigo Co's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Perrigo Co 3-Year Revenue Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Perrigo Co's 3-Year Revenue Growth Rate distribution charts can be found below:
* The bar in red indicates where Perrigo Co's 3-Year Revenue Growth Rate falls into.
This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
What does a 3-Year Revenue Growth Rate of -2.50% mean?
Perrigo Co (LTS:0Y5E) has a 3-Year Revenue Growth Rate of -2.50% as of Mar. 2026. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for Perrigo Co and its competitors. According to the industry distribution chart, Perrigo Co ranks #616 out of 899 companies in the Drug Manufacturers industry, placing it in the top 68.5%.
Is Perrigo Co's 3-Year Revenue Growth Rate too high?
Perrigo Co's current 3-Year Revenue Growth Rate is -2.50%. Based on the distribution chart, Perrigo Co ranks #616 out of 899 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Perrigo Co has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Perrigo Co's 3-Year Revenue Growth Rate compare to AMLX and HROW?
According to the Drug Manufacturers industry distribution chart, Perrigo Co ranks #616 out of 899 companies for 3-Year Revenue Growth Rate. This places Perrigo Co in the lower half of its industry. The industry median 3-Year Revenue Growth Rate is 4.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Revenue Growth Rate for a Drug Manufacturers company?
The median 3-Year Revenue Growth Rate among Drug Manufacturers companies is 4.10, based on 899 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Revenue Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Revenue Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Revenue Growth Rate mean?
A high 3-Year Revenue Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for Perrigo Co and its competitors. For the Drug Manufacturers industry, the median 3-Year Revenue Growth Rate is 4.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Perrigo Co's current 3-Year Revenue Growth Rate is -2.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Perrigo Co stock overvalued right now?
Based on GuruFocus' analysis, Perrigo Co (LTS:0Y5E) is currently considered Possible Value Trap. The stock's GF Value™ is $25.05, compared to a current price of $9.51 — trading 62% below its estimated fair value. The current 3-Year Revenue Growth Rate is -2.50%. Perrigo Co's overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Revenue Growth Rate calculated?
3-Year Revenue Growth Rate is calculated from a company's financial statements. For Perrigo Co (LTS:0Y5E), the current 3-Year Revenue Growth Rate is -2.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Perrigo Co (LTS:0Y5E) Overvalued in 2026?
Based on GuruFocus' analysis, Perrigo Co stock appears to be undervalued.
The current stock price of $9.51 is trading 62% below its estimated GF Value™ of $25.05.
GuruFocus considers Perrigo Co to be Possible Value Trap.
Key valuation signals for LTS:0Y5E:
3-Year Revenue Growth Rate: -2.50%
GF Value™: $25.05 vs. price of $9.51 (62% below fair value)
No single metric tells the full story. See the LTS:0Y5E stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo has divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two-thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
49GF Score
Get the complete analysis for LTS:0Y5E
3-Year Revenue Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0Y5E has been successfully added to your 